What they were paid
Phathom Pharmaceuticals Director Compensation Table · all 3 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $67,500 | $51,975 | $62,778 | $0 | $182,253 |
| FY2023 | $67,500 | $105,390 | $106,782 | $0 | $279,672 |
| FY2022 | $62,555 | $0 | $65,543 | — | $128,097 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Phathom Pharmaceuticals, Inc. DEF 14A filed April 7, 2026, accession 0001193125-26-144570, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Phathom Pharmaceuticals pays directors a $50,000 cash retainer.
Committees
FY2025 · as the proxy prints themCompensation · Nominating/Governance (Chair)
The rest of the Phathom Pharmaceuticals board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Frank Karbe | Independent Director | $176,420 |
| Heidi Kunz | Independent Director | $186,420 |
| James Topper | Independent Director | $169,753 |
| Mark Stenhouse | Independent Director | $173,920 |
| Michael F. Cola | Chair of the Board | $224,753 |
| Steven Basta | Director | $0 |
| Theodore R. Schroeder | Independent Director | $242,309 |
The full Phathom Pharmaceuticals compensation record
free company briefThis page is one director within Phathom Pharmaceuticals's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat